Signature program: a platform of basket trials.

Oncotarget 2018 Apr 20;9(30):21383-21395. Epub 2018 Apr 20.

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Investigating targeted therapies can be challenging due to diverse tumor mutations and slow patient accrual for clinical studies. The Signature Program is a series of 8 phase 2, agent-specific basket protocols using a rapid study start-up approach involving no predetermined study sites. Each protocol evaluated 1 agent (buparlisib, dovitinib, binimetinib, encorafenib, sonidegib, BGJ398, ceritinib, or ribociclib) in patients with solid or hematologic malignancies and an actionable mutation. The primary endpoint of each study was the clinical benefit rate (ie, complete or partial response, or stable disease) at 16 weeks. A total of 192 individual sites were opened in the United States, with a median start-up time of 3.6 weeks. The most common tumor types among the 595 treated patients were colorectal (9.2%), non-small cell lung adenocarcinoma (9.1%), and ovarian (8.4%). Frequent genetic alterations were in , , , and . Overall, 30 partial or complete responses were observed with 6 compounds in 16 tumor types. The Signature Program presents a unique and successful approach for rapid signal finding across multiple tumors and allowed various agents to be evaluated in patients with rare alterations. Incorporating these program features in conventional studies could lead to improved trial efficiencies and patient outcomes.

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/25109
Publisher Site
http://dx.doi.org/10.18632/oncotarget.25109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940401PMC
April 2018
11 Reads

Publication Analysis

Top Keywords

signature program
12
tumor types
8
tumors allowed
4
patients solid
4
ribociclib patients
4
84% frequent
4
ceritinib ribociclib
4
compounds tumor
4
weeks common
4
multiple tumors
4
malignancies actionable
4
finding multiple
4
time weeks
4
hematologic malignancies
4
bgj398 ceritinib
4
solid hematologic
4
sonidegib bgj398
4
buparlisib dovitinib
4
patients rare
4
rare alterations
4

Similar Publications